Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab
Authors' conclusion
In patients with acute myocardial infarction, elevated Lp(a) at baseline is associated with attenuation of plaque lipid regression despite intensive treatment with alirocumab plus high-intensity statin.
Study context
- Population
- Patients with acute MI265 with serial IVUS
- Participants
- 300 patients
- Comparison
- Higher vs lower baseline Lp(a) in patients treated with alirocumab vs placebo plus high-intensity statins
- Alirocumab Q4 Lp(a)n = 30
- Alirocumab Q1-Q3 Lp(a)n = 99reference
- Placebon = 134
- Primary endpoint
- Percent atheroma volume (IVUS), minimum fibrous cap thickness (OCT) and maxLCBI4mm (NIRS) in non-infarct-related arteries
- Follow-up
- 52 weeks
Primary result
As reported in the abstract
Change in maxLCBI4mm
Alirocumab Q4 Lp(a)
−40.2
interval −91.1–10.7
Alirocumab Q1-Q3 Lp(a)
−91.4
interval −113.9–-68.9
Placebo
−37.60
interval −57.40–-17.80
P = 0.01
Further findings
- Alirocumab: greater reductions in percent atheroma volume and maxLCBI4mm and greater increase in minimum fibrous cap thickness vs placebo
Original publication
Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab. Circ Cardiovasc Imaging. Published 19 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →